We’re pleased to announce that the U.S. FDA has granted Fast Track designation to first-in-class, small molecule MYB mRNA degrader, REM-422, for the treatment of recurrent, metastatic, or unresectable ACC.

bit.ly/4rC0UT5

#REM422 #AdenoidCysticCarcinoma

Remix’s Co-Founder and CEO was recently featured in Pharmaceutical Technology, highlighting how modulating RNA processing can dramatically expand the universe of druggable targets.
Read the article by Jam Bensilum here: bit.ly/4aKtGdL

#REM422 #RNAdegradation #RNAdegraders #RNAtherapeutics

Our CSO, Dom Reynolds, PhD, will be highlighting the development of REM-422 for ACC, AML, and high-risk MDS and how our REMaster™ platform is advancing RNA-targeted drug discovery at the 8th RNA-Targeted Drug Discovery & Development Summit. #REM422 #mRNA #RemixTherapeutics

📣Next week, Co-Founder & CEO, Pete Smith, will be presenting on an Oncology panel and part of a Q&A session at Evercore's Emerging Private Biotech Conference. Looking forward to discussing Remix’s approach to tackling diseases by modulating RNA processing with small molecules. #Evercore #REM422